Key achievements by the end of 2024:

• Funding: €829.43 million has been provided to support 437 grants.
• Clinical studies: 232 clinical studies received support from EDCTP2.
• Medical interventions: The EDCTP2 programme contributed to the development of five new or improved medical interventions to date, with more to follow:
  • An albendazole–ivermectin combination treatment for parasitic worm infections.
  • Arpraziquantel for treating schistosomiasis in young children.
  • Fexinidazole Winthrop for treating the acute form of sleeping sickness.
  • AmBisome® for treating HIV-associated cryptococcal meningitis.
  • The R21-Matrix malaria vaccine.
• Policy influence: Over 17 policy documents and guidelines have cited EDCTP-funded research.
• Publications: More than 2,000 peer-reviewed publications have acknowledged the contributions of the EDCTP2 programme.
• Membership growth: The EDCTP Association now includes 15 European countries and 30 African countries.
• Financial contributions: European Participating States contributed a total of €1.213 billion to the programme, exceeding the target of funding to match the €683 million from the European Union.
• Co-funding: €432.07 million has been raised in cash and in-kind contributions from partner organisations for EDCTP projects through strategic calls for proposals and other activities.

As the EDCTP2 programme concludes, our primary objectives are to ensure a successful transition into the next phase of the EDCTP Association and to maintain our commitment to equitable partnerships in global health.

Throughout its history, the EDCTP Association has prioritised equitable partnerships in all its activities—from governance to project management. This approach has positioned it as a key part of the EU’s Global Health Strategy and a model for how the EU and Africa can collaborate to address health challenges and enhance health security.

The success stories emerging from the EDCTP2 programme serve as a testament to the EU’s commitment to global health, particularly in addressing poverty-related diseases affecting sub-Saharan Africa. The ongoing Global Health EDCTP3 programme further reinforces this commitment as a key strategic priority.

The achievements highlighted in the EDCTP Annual Report 2024 demonstrate what can be achieved when partners in Europe, Africa, and beyond collaborate to improve health outcomes for some of the world’s most vulnerable populations. Despite the ongoing challenges faced, these partnerships are not only saving lives but also laying the foundation for stronger health research systems across sub-Saharan Africa.